Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel P Fishbein

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Texas Heart Institute Journal|May 9, 2014
Right ventricular sarcoidosis: is it time for updated diagnostic criteria?Kairav Vakil, Elina Minami, Daniel P Fishbein
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 20, 2007
Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipientsFanny Li, Kenneth W Kenyon, Katharine A Kirby, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|May 9, 2006
Expectant management is safe for cholelithiasis after heart transplantHiroo Takeyama, Mika N Sinanan, Daniel P Fishbein, et al.
Texas Heart Institute Journal|October 17, 2006
Open-chest management after heart transplantationHiroo Takayama, Richard J Leone, Gabriel S Aldea, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|February 3, 2007
Is pre-transplant vascular disease a risk factor for mortality and morbidity after heart transplantation?Hiroo Takayama, Avery B Nathens, Heather Merry, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|February 6, 2020
Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high-risk donor seropositive/recipient seronegative heart transplant recipientsHannah Imlay, Allison O Dumitriu Carcoana, Cynthia E Fisher, et al.
Journal of the American College of Cardiology|April 15, 2014
Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial)Daniel P Fishbein, Anne S Hellkamp, Daniel B Mark, et al.
The American Journal of Cardiology|June 14, 2005
Usefulness of relative lymphocyte count as an independent predictor of death/urgent transplant in heart failureKier V Huehnergarth, Dariush Mozaffarian, Mark D Sullivan, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|June 19, 2010
Predictive value of the Seattle Heart Failure Model in patients undergoing left ventricular assist device placementEric S Ketchum, Alec J Moorman, Daniel P Fishbein, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 19, 2022
TTR variants in patients with dilated cardiomyopathy: An investigation of the DCM Precision Medicine StudyBarry H Trachtenberg, Javier Jimenez, Alanna A Morris, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Texas Heart Institute Journal|May 9, 2014
Right ventricular sarcoidosis: is it time for updated diagnostic criteria?Kairav Vakil, Elina Minami, Daniel P Fishbein
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 20, 2007
Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipientsFanny Li, Kenneth W Kenyon, Katharine A Kirby, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|May 9, 2006
Expectant management is safe for cholelithiasis after heart transplantHiroo Takeyama, Mika N Sinanan, Daniel P Fishbein, et al.
Texas Heart Institute Journal|October 17, 2006
Open-chest management after heart transplantationHiroo Takayama, Richard J Leone, Gabriel S Aldea, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|February 3, 2007
Is pre-transplant vascular disease a risk factor for mortality and morbidity after heart transplantation?Hiroo Takayama, Avery B Nathens, Heather Merry, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|February 6, 2020
Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high-risk donor seropositive/recipient seronegative heart transplant recipientsHannah Imlay, Allison O Dumitriu Carcoana, Cynthia E Fisher, et al.
Journal of the American College of Cardiology|April 15, 2014
Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial)Daniel P Fishbein, Anne S Hellkamp, Daniel B Mark, et al.
The American Journal of Cardiology|June 14, 2005
Usefulness of relative lymphocyte count as an independent predictor of death/urgent transplant in heart failureKier V Huehnergarth, Dariush Mozaffarian, Mark D Sullivan, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|June 19, 2010
Predictive value of the Seattle Heart Failure Model in patients undergoing left ventricular assist device placementEric S Ketchum, Alec J Moorman, Daniel P Fishbein, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 19, 2022
TTR variants in patients with dilated cardiomyopathy: An investigation of the DCM Precision Medicine StudyBarry H Trachtenberg, Javier Jimenez, Alanna A Morris, et al.
Pageof 3